Skip to main content
. 2023 Sep 1;10:1239869. doi: 10.3389/fmed.2023.1239869

Figure 1.

Figure 1

Skin condition of patients. (A) At 0 and 2 weeks of abrocitinib treatment. (B) Case 2, at 0, 2, and 4 weeks of abrocitinib treatment. (C) Case 3, at 0, 2, and 4 weeks of abrocitinib treatment. (D) Case 4, at 0 and 2 weeks of abrocitinib treatment.